← Leaderboards
Lisa Bodei
Sloan-Kettering Inst Can Research
$1,419,480
Attributed
$1,419,480
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $715.1K · FY2024–25$1M$750K$500K$250K$0
'24
'25
Funding mix
By agency
NIH$1,419,480 · 1
By mechanism
R01$1,419,480 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Ping Mu$4,365,544
- John Thomas Poirier$4,490,380
- Donna Pauler Ankerst$1,167,446
- Brian Matthew Zeglis$6,881,872
- Hedvig Hricak$10,655,349
Others in their field
Other Rising Stars on “Advanced Prostate Cancer”
- Remi Adelaiye-Ogala · State University Of New York At Buffalo$2,864,216
- Russell K. Pachynski · Washington University$2,036,989
- Ph.d., Peymon Ghazi · Malcova Inc$1,998,128
- Johannes F Fahrmann · University Of Tx Md Anderson Can Ctr$1,983,279
- Rajesh Krishnan · Oncternal Therapeutics, Inc.$1,810,779
- Zhiguo Li · University Of Kentucky$1,749,738
Research focus
Advanced Prostate CancerAftercareAffectAntibodiesAntigensBiologicalBiopsyBloodBoneBone ImagingCancer EtiologyCancer PatientCancer TypeCell SurfaceCessation Of LifeCommon Terminology Criteria For Adverse EventsDiagnosisDiagnosticDoseDosimetryExhibitsGene ExpressionGeneticGenomics
Grant awards (2)
Characterizing the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostate$715,058
R01 · FY2025 · CA · contact PI
Characterizing the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostate$704,422
R01 · FY2024 · CA · contact PI